Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eprosartan is an angiotensin II receptor blocker (ARB) used primarily to treat high blood pressure (hypertension). It works by selectively blocking the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This blockade leads to vasodilation, reduced secretion of vasopressin and aldosterone, and ultimately a decrease in blood pressure. Eprosartan does not exhibit partial agonist activity at the AT1 receptor and has a much higher affinity for this receptor compared to AT2 receptors. It is available as an oral tablet and may be used alone or with other antihypertensive agents such as diuretics or calcium channel blockers. In addition to hypertension, it is sometimes used off-label for heart failure and diabetic nephropathy[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eprosartan.